Drugs / ATV-1601
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07038369 | Jul 2025 → Aug 2028 expected | cervical carcinoma, endometrial carcinoma, estrogen-receptor positive breast cancer, fallopian tube cancer +3 | Atavistik Bio, Inc | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07601425 | Jun 2026 → Dec 2027 expected | hereditary hemorrhagic telangiectasia | Atavistik Bio, Inc | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATV-1601 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07038369 ↗ |
| Action | Inhibit | “Selective AKT1 E17K Allosteric Inhibitor” NCT07038369 ↗ |
| Route | Oral | “ATV-1601 administered orally” NCT07038369 ↗ |
| Target | AKT1 | “Selective AKT1 E17K Allosteric Inhibitor” NCT07038369 ↗ |